The Efficacy of High Dose Dexamethasone Therapy in Children with Immune Thrombocytopenic Purpura / 임상소아혈액종양
Clinical Pediatric Hematology-Oncology
; : 102-107, 2018.
Article
en En
| WPRIM
| ID: wpr-717647
Biblioteca responsable:
WPRO
ABSTRACT
BACKGROUND: Few studies of high dose dexamethasone (HD-DXM) therapy in children with immune thrombocytopenic purpura (ITP) have been reported. The purpose of this study is to investigate efficacy and safety of repeated HD-DXM therapy as second-line treatment of ITP in childhood. METHODS: We retrospectively analyzed the medical records of patients < 18 years of age with primary ITP who received more than 2 cycles of HD-DXM therapy from May 2004 to January 2018. HD-DXM was given orally in 4-day pulses every 28 days as a 20–40 mg/1.73 m² daily dose. RESULTS: A total of 26 patients (male, 19; female, 7) were enrolled and their median age was 6 years (range, 1–15). All patients had received previous treatment for ITP. A median 6 cycles (range, 2–19) of HD-DXM was given. On the beginning of HD-DXM therapy, three patients satisfied the criteria for newly diagnosed ITP, 16 for persistent ITP and 7 for chronic ITP. Relapse-free survival (RFS) of responders (n=9) after the last HD-DXM cycle was estimated to be 38.1±17.2%, lasting for a median 9.1 months (range, 5.6–46.2). According to response after the 2nd cycle, RFS of responders (n=13) was significantly higher than non-responders (23.1±11.7% vs. 7.7%±7.4%, P=0.001). The most common adverse event was irritability (30.8%), followed by fatigue (19.2%). CONCLUSION: HD-DXM therapy in children was relatively tolerated and response after therapy was acceptable. More courses of HD-DXM may be feasible in responders after two cycles of HD-DXM.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Dexametasona
/
Registros Médicos
/
Estudios Retrospectivos
/
Púrpura Trombocitopénica Idiopática
/
Fatiga
Tipo de estudio:
Observational_studies
Límite:
Child
/
Female
/
Humans
Idioma:
En
Revista:
Clinical Pediatric Hematology-Oncology
Año:
2018
Tipo del documento:
Article